Andrew Nick, Gabb Genevieve, Del Fante Matthew
Department of Medicine, Royal Adelaide Hospital, South Australia, Australia.
Aust Fam Physician. 2011 Dec;40(12):985-8.
Angioedema is an infrequent but potentially serious adverse effect of angiotensin converting enzyme inhibitors (ACEIs).
This article describes a case of ACEI associated angioedema and reviews important clinical features of the condition.
The mechanism of ACEI associated angioedema is not allergic (histamine mediated), but rather due to an alteration of the balance of bradykinin and other vasodilator mediators. Onset may be delayed for weeks, months or years and episodes may be recurrent. Occasionally, airway obstruction may occur. Diagnosis is from history and physical examination; there is no specific diagnostic test. In contrast to allergic angioedema, ACEI associated angioedema is generally unresponsive to corticosteroids and antihistamines, although these agents are often used by convention. In the longer term, cessation of the ACEI is necessary to reduce the risk of recurrent episodes.
血管性水肿是血管紧张素转换酶抑制剂(ACEI)一种罕见但可能严重的不良反应。
本文描述了一例与ACEI相关的血管性水肿病例,并综述了该病症的重要临床特征。
与ACEI相关的血管性水肿的机制并非过敏性(组胺介导),而是由于缓激肽和其他血管舒张介质平衡的改变。发病可能延迟数周、数月或数年,且发作可能反复出现。偶尔会发生气道阻塞。诊断依据病史和体格检查;没有特异性诊断测试。与过敏性血管性水肿不同,尽管通常会使用皮质类固醇和抗组胺药,但与ACEI相关的血管性水肿通常对这些药物无反应。从长远来看,停用ACEI对于降低复发风险是必要的。